Identifying chelators for metalloprotein inhibitors using a fragment-based approach

Journal of Medicinal Chemistry

Volumn 54, Issue 2, 2011, Pages 591-602

  Jacobsen, Jennifer A ^a   Fullagar, Jessica L ^a   Miller, Melissa T ^a   Cohen, Seth M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL; BENZOXIQUINE; CHELATING AGENT; ENZYME INHIBITOR; LEAD; LIGAND; METALLOPROTEIN; METALLOPROTEINASE;

ANTHRAX; ARTICLE; IC 50; LETHAL GENE; METAL BINDING;

ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CHELATING AGENTS; COPPER; DRUG DESIGN; HUMANS; HYDROXYQUINOLINES; IRON; LIGANDS; LIPOXYGENASE INHIBITORS; MATRIX METALLOPROTEINASES; MONOPHENOL MONOOXYGENASE; NITRIC OXIDE SYNTHASE TYPE II; RECOMBINANT PROTEINS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; ZINC;

EID: 78751661570     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101266s     Document Type: Article

References (80)

1. Lu, Y. Metalloprotein and metallo-DNA/RNAzyme design: Current approaches, success measures, and future challenges Inorg. Chem. 2006, 45, 9930-9940
2. McRae, R.; Bagchi, P.; Sumalekshmy, S.; Fahrni, C. J. In situ imaging of metal in cells and tissues Chem. Rev. 2009, 109, 4780-4827
3. Seffernick, J. L.; McTavish, H.; Osborne, J. P.; de Souza, M. L.; Sadowsky, M. J.; Wackett, L. P. Atrazine chlorohydrolase from Pseudomonas sp. strain ADP is a metalloenzyme Biochemistry 2002, 41, 14430-14437
4. Hou, C.-X.; Dirk, L. M. A.; Goodman, J. P.; Williams, M. A. Metabolism of the peptide deformylase inhibitor actinonin in tobacco Weed Sci. 2006, 54, 246-254
5. Biou, V.; Dumas, R.; Cohen-Addad, C.; Douce, R.; Job, D.; Pebay-Peyroula, E. The crystal structure of plant acetohydroxy acid isomeroreductase complexed with NADPH, two magnesium ions and a herbicidal transition state analog determined at 1.65 Å resolution EMBO J. 1997, 16, 3405-3415
6. Parvez, S.; Kang, M.; Chung, H.-S.; Bae, H. Naturally occuring tyrosinase inhibitors: Mechanism and applications in skin health, cosmetics and agriculture industries Phytother. Res. 2007, 21, 805-816
7. Smit, N.; Vicanova, J.; Pavel, S. The hunt for natural skin whitening agents Int. J. Mol. Sci. 2009, 10, 5326-5349
8. Ma, X.; Ezzeldin, H. H.; Diasio, R. B. Histone deacetylase inhibitors: Current status and overview of recent clinical trials Drugs 2009, 69, 1911-1934
9. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 2002, 295, 2387-2392
10. Sousa, S. F.; Fernandes, P. A.; Ramos, M. J. Farnesyltransferase inhibitors: A detailed chemical view on an elusive biological problem Curr. Med. Chem. 2008, 15, 1478-1492
11. Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Ribonucleotide reductase inhibitors and future drug design Curr. Cancer Drug Targets 2006, 6, 409-431
12. Cristalli, G.; Costanzi, S.; Lambertucci, C.; Lupidi, G.; Vittori, S.; Volpini, R.; Camaioni, E. Adenosine deaminase: Functional implications and different classes of inhibitors Med. Res. Rev. 2001, 21, 105-128
13. Moss, M. L.; Sklair-Tavron, L.; Nudelman, R. Drug insight: Tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis Nat. Clin. Pract. Rheumatol. 2008, 4, 300-309
14. Burnett, J. C.; Henchal, E. A.; Schmaljohn, A. L.; Bavari, S. The evolving field of biodefence: Therapeutic developments and diagnostics Nat. Rev. Drug Discovery 2005, 4, 281-297
15. Hernick, M.; Fierke, C. A. Zinc hydrolases: The mechanisms of zinc-dependent deacetylases Arch. Biochem. Biophys. 2005, 433, 71-84
16. Villain-Guillot, P.; Bastide, L.; Gualtieri, M.; Leonetti, J.-P. Progress in targeting bacterial transcription Drug Discovery Today 2007, 12, 200-208
17. Dubey, S.; Satyanarayana, Y. D.; Lavania, H. Development of integrase inhibitors for treatment of AIDS: An overview Eur. J. Med. Chem. 2007, 42, 1159-1168
18. White, R. J.; Margolis, P. S.; Trias, J.; Yuan, Z. Targeting metalloenzymes: A strategy that works Curr. Opin. Pharmacol. 2003, 3, 502-507
19. Vaughan, M. D.; Sampson, P. B.; Honek, J. F. Methionine in and out of proteins: Targets for drug design Curr. Med. Chem. 2002, 9, 385-409
20. Dive, V.; Chang, C.-F.; Yiotakis, A.; Sturrock, E. D. Inhibition of zinc metallopeptidases in cardiovascular disease: From unity to trinity, or duality? Curr. Pharm. Des. 2009, 15, 3606-3621
21. Dunkel, P.; Gelain, A.; Barlocco, D.; Haider, N.; Gyires, K.; Sperlagh, B.; Magyar, K.; Maccioni, E.; Fadda, A.; Matyus, P. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: Recent developments concerning substrates and inhibitors of a promising therapeutic target Curr. Med. Chem. 2008, 15, 1827-1839
22. Mai, A.; Rotili, D.; Valente, S.; Kazantsev, A. G. Histone deacetylase inhibitors and neurodegenerative disorders: Holding the promise Curr. Pharm. Des. 2009, 15, 3940-3957
23. Jacobsen, J. A.; Jourden, J. L. M.; Miller, M. T.; Cohen, S. M. To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition Biochim. Biophys. Acta 2010, 1803, 72-94
24. Puerta, D. T.; Cohen, S. M. A bioinorganic perspective on matrix metalloproteinase inhibition Curr. Top. Med. Chem. 2004, 4, 1551-1573
25. Muri, E. M. F.; Nieto, M. J.; Sindelar, R. D.; Williamson, J. S. Hydoxamic acids as pharmacological agents Curr. Med. Chem. 2002, 9, 1631-1653
26. Puerta, D. T.; Lewis, J. A.; Cohen, S. M. New beginnings for matrix metalloproteinase inhibitors: Identification of high-affinity zinc-binding groups J. Am. Chem. Soc. 2004, 126, 8388-8389
27. Puerta, D. T.; Mongan, J.; Tran, B. L.; McCammon, J. A.; Cohen, S. M. Potent, selective pyrone-based inhibitors of stromelysin-1 J. Am. Chem. Soc. 2005, 127, 14148-14149
28. Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. A new role for old ligands: Discerning chelators for zinc metalloproteinases J. Am. Chem. Soc. 2006, 128, 3156-3157
29. Jacobsen, F. E.; Buczynski, M. W.; Dennis, E. A.; Cohen, S. M. A macrophage cell model for selective metalloproteinase inhibitor design ChemBioChem 2008, 9, 2087-2095
30. Agrawal, A.; Romero-Perez, D.; Jacobsen, J. A.; Villarreal, F. J.; Cohen, S. M. Zinc-binding groups modulate selective inhibition of MMPs ChemMedChem 2008, 3, 812-820
31. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and therapeutic application of matrix metalloproteinase inhibitors Chem. Rev. 1999, 99, 2735-2776
32. Brown, S.; Meroueh, S. O.; Fridman, R.; Mobashery, S. Quest for selectivity in inhibition of matrix metalloproteinases Curr. Top. Med. Chem. 2004, 4, 1227-1238
33. Suzuki, T.; Miyata, N. Rational design of non-hydroxamate histone deacetylase inhibitors Mini-Rev. Med. Chem. 2006, 6, 515-526
34. Winum, J.-Y.; Scozzafava, A.; Montero, J.-L.; Supuran, C. T. Design of zinc binding functions for carbonic anhydrase inhibitors Curr. Pharm. Des. 2008, 14, 615-621
35. Johnson, S. L.; Jung, D.; Forino, M.; Chen, Y.; Satterthwait, A.; Rozanov, D. V.; Strongin, A. Y.; Pellecchia, M. Anthrax lethal factor protease inhibitors: Synthesis, SAR, and structure-based 3D QSAR studies J. Med. Chem. 2006, 49, 27-30
36. Hajduk, P. J.; Shuker, S. B.; Nettesheim, D. G.; Craig, R.; Augeri, D. J.; Betebenner, D.; Albert, D. H.; Guo, Y.; Meadows, R. P.; Xu, L.; Michaelides, M.; Davidsen, S. K.; Fesik, S. W. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability J. Med. Chem. 2002, 45, 5628-5639
37. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Paz, O. G.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection J. Med. Chem. 2008, 51, 5843-5855
38. Johnson, S. L.; Chen, L.-H.; Barile, E.; Emdadi, A.; Sabet, M.; Yuan, H.; Wei, J.; Guiney, D.; Pellecchia, M. Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors Bioorg. Med. Chem. 2009, 17, 3352-3368
39. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680
40. Leach, A. R.; Hann, M. M.; Burrows, J. N.; Griffen, E. J. Fragment screening: An introduction Mol. Biosyst. 2006, 2, 429-446
41. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
42. Agrawal, A.; Johnson, S. L.; Jacobsen, J. A.; Miller, M. T.; Chen, L.-H.; Pellecchia, M.; Cohen, S. M. Chelator fragment libraries for targeting metalloproteinases ChemMedChem 2010, 5, 195-199
43. Puerta, D. T.; Cohen, S. M. Elucidating drug-metalloprotein interactions with tris(pyrazolyl)borate model complexes Inorg. Chem. 2002, 41, 5075-5082
44. Puerta, D. T.; Cohen, S. M. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors Inorg. Chem. 2003, 42, 3423-3430
45. Puerta, D. T.; Schames, J. R.; Henchman, R. H.; McCammon, J. A.; Cohen, S. M. From model complexes to metalloprotein inhibition: A synergistic approach to structure-based drug discovery Angew. Chem., Int. Ed. 2003, 42, 3772-3774
46. Hohwy, M.; Spadola, L.; Lundquist, B.; Hawtin, P.; Dahmen, J.; Groth-Clausen, I.; Nilsson, E.; Persdotter, S.; von Wachenfeldt, K.; Folmer, R. H. A.; Edman, K. Novel prostaglandin d synthase inhibitors generated by fragment-based drug design J. Med. Chem. 2008, 51, 2178-2186
47. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.; Carrera, G. M., Jr.; Marcotte, P. A.; J, S.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR J. Am. Chem. Soc. 1997, 119, 5818-5827
48. Charton, J.; Deprez, B. P.; Deprez-Poulain, R. F. Synthesis of a 200-member library of squaric acid N -hydroxylamide amides Bioorg. Med. Chem. Lett. 2008, 18, 4968-4971
49. Wang, J.; Uttamchandani, M.; Li, J.; Mingyu, H.; Yao, S. Q. Rapid assembly of matrix metalloprotease inhibitors using click chemistry Org. Lett. 2006, 8, 3821-3824
50. Hu, M.; Li, J.; Yao, S. Q. In situ click assembly of small molecule matrix metalloprotease inhibitors containing zinc-chelating groups Org. Lett. 2008, 10, 5529-5531
51. Hofmann, B.; Franke, L.; Proschak, E.; Tanrikulu, Y.; Schneider, P.; Steinhilber, D.; Schneider, G. Scaffold-hopping cascade yields potent inhibitors of 5-lipoxygenase ChemMedChem 2008, 3, 1535-1538
52. Nordstrom, H.; Gossas, T.; Hamalainen, M.; Kallblad, P.; Nystrom, S.; Wallberg, H.; Danielson, U. H. Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library J. Med. Chem. 2008, 51, 3449-3459
53. 3+ values J. Med. Chem. 1999, 42, 4814-4823
54. Lewis, J. A.; Puerta, D. T.; Cohen, S. M. Metal complexes of the trans -influencing ligand thiomaltol Inorg. Chem. 2003, 42, 7455-7459
55. Lewis, J. A.; Cohen, S. M. Addressing lead toxicity: Complexation of lead(II) with thiopyrone and hydroxypyridinethione O,S mixed chelators Inorg. Chem. 2004, 43, 6534-6536
56. Yan, Y.-L.; Miller, M. T.; Cao, Y.; Cohen, S. M. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: Developing a structure-activity relationship Bioorg. Med. Chem. Lett. 2009, 19, 1970-1976
57. Yan, Y.-L.; Cohen, S. M. Efficient synthesis of 5-amido-3-hydroxy-4- pyrones as inhibitors of matrix metalloproteinases Org. Lett. 2007, 9, 2517-2520
58. 3+ values Bioorg. Med. Chem. 2001, 9, 563-573
59. Wiley, R. H.; Jarboe, C. H. 2-Pyrones. XIX. 3-Hydroxy-2-pyrone and 4-arylhydrazono-2,3-pyranones J. Am. Chem. Soc. 1956, 78, 2398-2401
60. Smith, A. P.; Corbin, P. S.; Fraser, C. L. An improved synthesis of hydroxymethyl bipyridines Tet. Lett. 2000, 41, 2787-2789
61. Rouffet, M.; de Oliveira, C. A. F.; Udi, Y.; Agrawal, A.; Sagi, I.; McCammon, J. A.; Cohen, S. M. From sensors to silencers: Quinoline- and benzimidazole-sulfonamides as inhibitors for zinc proteases J. Am. Chem. Soc. 2010, 132, 8232-8233
62. Liu, J.; Yi, W.; Wan, Y.; Ma, L.; Song, H. 1-(1-Arylethylidene) thiosemicarbazide derivatives: A new class of tyrosinase inhibitors Bioorg. Med. Chem. 2008, 16, 1096-1102
63. Pufahl, R. A.; Kasten, T. P.; Hills, R.; Gierse, J. K.; Reiz, B. A.; Weinberg, R. A.; Masferrer, J. L. Development of a fluorescence-based assay of human 5-lipoxygenase Anal. Biochem. 2007, 364, 204-212
64. Puerta, D. T.; Griffin, M. O.; Lewis, J. A.; Romero-Perez, D.; Garcia, R.; Villarreal, F. J.; Cohen, S. M. Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity J. Biol. Inorg. Chem. 2006, 11, 131-138
65. Lewis, J. A.; Mongan, J.; McCammon, J. A.; Cohen, S. M. Evaluation and binding-mode prediction of thiopyrone-based inhibitors of anthrax lethal factor ChemMedChem 2006, 1, 694-697
66. Chowdhury, M. A.; Abdellatif, K. R. A.; Dong, Y.; Das, D.; Suresh, M. R.; Knaus, E. E. Synthesis of celecoxib analogues possessing a N -difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: Biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity J. Med. Chem. 2009, 52, 1525-1529
67. Chowdhury, M. A.; Chen, H.; Abdellatif, K. R. A.; Dong, Y.; Petruk, K. C.; Knaus, E. E. Synthesis and biological evaluation of 1-(benzenesulfonamido)- 2-[5-(N -hydroxypyridin-2(1 H)-one)]acetylene regioisomers: A novel class of 5-lipoxygenase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4195-4198
68. Chowdhury, M. A.; Chen, H.; Abdellatif, K. R. A.; Dong, Y.; Petruk, K. C.; Knaus, E. E. Synthesis of new 1-(2-, 3-, or 4-methanesulfonylphenyl)-2-[5-(N -hydroxypyridin-2(1 H)-one)]acetylene regioisomers: A search for novel cyclooxygenase and lipoxygenase inhibitors J. Heterocycl. Chem. 2009, 46, 58-61
69. Peyroux, E.; Ghattas, W.; Hardre, R.; Giorgi, M.; Faure, B.; Simaan, A. J.; Belle, C.; Reglier, M. Binding of 2-hydroxypyridine- N -oxide on dicopper(II) centers: Insights into tyrosinase inhibition mechanism by transition-state analogs Inorg. Chem. 2009, 48, 10874-10876
70. Jimenez, M.; Garcia-Carmona, F. 4-Substituted resorcinols (sulfite alternatives) as slow-binding inhibitors of tyrosinase catecholase activity J. Agric. Food Chem. 1997, 45, 2061-2065
71. Hider, R. C.; Lerch, K. The inhibition of tyrosinase by pyridinones Biochem. J. 1989, 257, 289-290
72. Bursavich, M. G.; Lombardi, S.; Gilbert, A. M.; Laakso, L. M.; Khafizova, G.; How, D. B.; Sabatini, J. J.; Sum, P.-E.; Clemens, J. J. U.S. Patent WO/2008/024922, 2008.
73. Li, J. J. U.S. Patent WO/2004/014377, 2004.
74. Musser, J. H.; Jones, H.; Sciortino, S.; Bailery, K.; Coutts, S. M.; Khandwala, A.; Sonnino-Goldman, P.; Leibowitz, M.; Wolf, P.; Neiss, E. S. Synthesis and antiallergic activities of 1,3-oxazolo[4,5- h ]quinolines J. Med. Chem. 1985, 28, 1255-1259
75. Johnson, L. L.; Pavlovsky, A. G.; Johnson, A. R.; Janowicz, J. A.; Man, C.-F.; Ortwine, D. F.; Purchase, C. F.; White, A. D.; Hupe, D. J. A rationalization of the acidic pH dependence for stromelysin-1 (matrix metalloprotease-3) catalysis and inhibition J. Biol. Chem. 2000, 275, 11026-11033
76. Aureli, L.; Gioia, M.; Cerbara, I.; Monaco, S.; Fasciglione, G. F.; Marini, S.; Ascenzi, P.; Topai, A.; Coletta, M. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases Curr. Med. Chem. 2008, 15, 2192-2222
77. Collier, R. J.; Young, J. A. T. Anthrax toxin Annu. Rev. Cell Dev. Biol. 2003, 19, 45-70
78. Massova, I.; Kotra, L. P.; Mobashery, S. Structural insight into the binding motifs for the calcium ion and the non-catalytic zinc in matrix metalloproteases Bioorg. Med. Chem. Lett. 1998, 8, 853-858
79. Turk, B. E.; Wong, T. Y.; Schwarzenbacher, R.; Jarrell, E. T.; Leppla, S. H.; Collier, R. J.; Liddington, R. C.; Cantley, L. C. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor Nat. Struct. Mol. Biol. 2004, 11, 60-66
80. Milbank, J. B. J.; Stevenson, R. J.; Ware, D. C.; Chang, J. Y. C.; Tercel, M.; Ahn, G.-O.; Wilson, W. R.; Denny, W. A. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5, 6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1 H -pyrrolo[3,2- f ]quinoline(seco -6-azaCBI-TMI) as hypoxia selective cytotoxins J. Med. Chem. 2009, 52, 6822-6834